In this video, Professor Dame Lesley Fallowfield explains why oncologists need to be aware of their own tolerance of uncertainty before discussing possible treatment risks and outcomes with patients.
In this video, Professor Dame Lesley Fallowfield explains why oncologists need to be aware of their own tolerance of uncertainty before discussing possible treatment risks and outcomes with patients.
Frontline Chemo-Free Regimen Supported in HR+/HER2+ Breast Cancer Therapy
January 1st 2024Combining anastrozole with palbociclib, trastuzumab, and pertuzumab as a frontline therapy for hormone receptor–positive, HER2-positive breast cancer may avoid some of the toxicities associated with chemotherapy, says Amy Tiersten, MD.